Association of P2Y12 Gene Promoter DNA Methylation with the Risk of Clopidogrel Resistance in Coronary Artery Disease Patients

Table 2

Characteristics comparison between CR and non-CR.

	Cases (𝑛=49)	Controls (𝑛=57)	𝑃 value
Male gender, 𝑛 (%)	35 (71.43)	46 (80.70)	0.262
Hypertension, 𝑛 (%)	36 (73.47)	36 (63.16)	0.257
Diabetes mellitus, 𝑛 (%)	10 (20.41)	13 (22.81)	0.765
Dyslipidemia, 𝑛 (%)	20 (40.82)	26 (45.61)	0.619
Current smoking, 𝑛 (%)	19 (38.78)	21 (36.84)	0.838
Alcohol abuse	9 (18.37)	10 (17.54)	0.912
Age, y	65.20±11.50	61.74±11.11	0.120
BMI, kg/m^2,	23.84±2.86	24.05±2.74	0.695
Number of stents per patient	1.55±0.98	1.28±0.77	0.116
Left ventricular ejection fraction, %	59.04±10.07	61.75±7.45	0.115
Total cholesterol, mg/dL	4.57±1.24	4.80±1.36	0.382
Triglycerides, mg/dL	1.70±1.02	1.73±1.30	0.907
HDL cholesterol, mg/dL	0.95±0.23	0.98±0.31	0.608
LDL cholesterol, mg/dL	2.81±1.06	2.96±0.99	0.459
GLU, mmol/L	6.12±2.42	5.69±1.75	0.284
HbA1c, %	6.23±1.31	6.22±1.42	0.972
ALT, umol/L	39.67±32.75	38.95±31.56	0.908
AST, umol/L	125.27±183.75	126.30±183.16	0.977
TBIL, umol/L	15.54±9.21	14.35±7.42	0.464
Albumin (A), g/L	37.73±5.03	39.95±5.02	0.026
BUN, mmol/L	5.83±2.10	5.61±2.30	0.618
CREA, mmol/L	72.53±20.33	71.56±20.06	0.807
UA, umol/L	342.71±102.48	321.26±84.86	0.241
hsCRP, mg/L	10.13±17.91	12.00±21.95	0.636
PLT, ∗10^9/L	191.22±61.93	208.35±85.68	0.248
MPV, fL	8.47±1.40	8.03±0.89	0.058
PCT, %	0.16±0.04	0.17±0.05	0.375
PDW, %	16.37±0.63	16.32±0.52	0.664
P2Y12 CpG1, (%)	43.31±10.96	44.89±9.26	0.420
P2Y12 CpG2, (%)	37.00±7.52	37.32±6.82	0.821